Personalizing
Cancer Treatment for Everyone

PUBLISHED RESEARCH
Massive Bio Announces First Patient Enrolled in Its Pivotal Global SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Massive Bio, Inc., a leader in providing simplified and affordable access to precision oncology to cancer patients treated at community-based oncology practices, announced today that the first patient has been enrolled in a global registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool powered by a virtual tumor board (VTB) program. This registry will assess its clinical impact on world-wide patients with advanced cancer to facilitate clinical trial enrollment (CTE), as well as financial impact.

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.

Carriers of germ-line mutations in BRCA1 and BRCA2 from families at high risk for cancer have been estimated to have an 85 percent risk of breast cancer. Since the combined frequency of BRCA1 and BRCA2 mutations exceeds 2 percent among Ashkenazi Jews, we were able to estimate the risk of cancer in a large group of Jewish men and women from the Washington, D.C., area.

 

Considerations and Advancements of Precision Medicine in GI Cancers

This activity is designed to inform physicians about the current availability and use of targeted therapies and precision medicine in gastric (GC) and other gastrointestinal (GI) cancers.

 

Oral Versus IV Oncolytics

Here, we have oral drugs. How do these oral oncolytics compare to the parenteral drugs–the only drugs, really, when I was growing up in medicine–in terms of use and in terms of access?

 

Follicular Lymphoma Regimens Equivalent

Two widely used regimens for advanced-stage follicular lymphoma led to similar high rates of long-term survival, as reported in the Journal of Clinical Oncology.

 

Extended AI Can Stop after 2 Years

Continuing adjuvant aromatase inhibitor (AI) therapy for 2 years beyond the current standard 5 years of treatment yielded the same level of recurrence prevention as continuing the treatment for an extra 5 years, according to a report at the San Antonio Breast Cancer Symposium.

 

FDA Approves NGS Test for Multiple Mutations

The FDA approved a next-generation sequencing test that can detect multiple mutations in any solid tumor.

 

Radical Treatment of the Primary Tumor in Metastatic Bladder Cancer: Potentially Dangerous Findings From Observational Data

Population-based observational studies allow investigators to evaluate the adoption of new therapies and to determine whether benefits seen in clinical trials are realized in the real world.

 

Clinical outcome of patients with metastatic renal cell carcinoma who interrupted VEGFR-TKI after achieving stable disease or better response.

The purpose of the this study is to evaluate the clinical outcome of VEGFR-TKIs interruption in patients with metastatic renal cell carcinoma (mRCC) after achieving stable disease (SD) or better response.

Tumor Heterogeneity Predicts Metastatic Potential in Colorectal Cancer

Tumors continuously evolve to maintain growth; secondary mutations facilitate this process, resulting in high tumor heterogeneity. In this study, we compared mutations in paired primary and metastatic colorectal cancer tumor samples to determine whether tumor heterogeneity can predict tumor metastasis.

Overall Survival Rate Increased in Gastric Cancer

Docetaxel-based chemotherapy led to significant improvement in progression-free (PFS) and overall survival for patients with resectable gastric or gastroesophageal juncture (GEJ) cancer, according to a study reported at the European Society for Medical Oncology conference in Madrid.

Stay in Touch with Us

To speak with a dedicated cancer care specialist, contact us by one of the options listed below:

PLEASE FILL OUT FORM BELOW

X
Talk to Cancer Care Experts
Talk to Cancer Care Experts:
+1 (844) 627-7246
Top